Key facts
- This page summarizes Abraham Ceesay's Form 4 filing for Cerevel Therapeutics Holdings, Inc..
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 08 Feb 2023, 19:29.
Abraham Ceesay - 06 Feb 2023 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.
- Reporting relationship
- President
- Issuer ticker
- N/A
- Reported as of
- 06 Feb 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 08 Feb 2023, 19:29:19 UTC
- Prior SEC filing
- 12 Sep 2022
- Next SEC filing
- 11 Oct 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Bodenrader, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Abraham Ceesay filed Form 4 for Cerevel Therapeutics Holdings, Inc. on 08 Feb 2023.
Change
- Previous filing in this sequence was filed on 12 Sep 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CERE
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +114,445
- Change %
- Price
- $0.000000
- Shares after
- 114,445
- Date
- 06 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 114,445
- Exercise price
- $34.41
- Footnotes
- F1
CERE
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +29,083
- Change %
- Price
- $0.000000
- Shares after
- 29,083
- Date
- 06 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 29,083
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
25% of this option shall vest and become exercisable on February 6, 2024, with the remainder vesting in thirty-six (36) monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Footnote F2
The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock.
Footnote F3
The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date.